DE69008476D1 - Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose. - Google Patents

Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose.

Info

Publication number
DE69008476D1
DE69008476D1 DE69008476T DE69008476T DE69008476D1 DE 69008476 D1 DE69008476 D1 DE 69008476D1 DE 69008476 T DE69008476 T DE 69008476T DE 69008476 T DE69008476 T DE 69008476T DE 69008476 D1 DE69008476 D1 DE 69008476D1
Authority
DE
Germany
Prior art keywords
treatment
pharmaceutical composition
osteoporosis
estrogen
thyroid hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69008476T
Other languages
English (en)
Other versions
DE69008476T2 (de
Inventor
Tomoshi Miura
Shinichiro Aonuma
Hiroyuki Ohara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Publication of DE69008476D1 publication Critical patent/DE69008476D1/de
Application granted granted Critical
Publication of DE69008476T2 publication Critical patent/DE69008476T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69008476T 1989-10-26 1990-10-26 Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose. Expired - Fee Related DE69008476T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28114189 1989-10-26

Publications (2)

Publication Number Publication Date
DE69008476D1 true DE69008476D1 (de) 1994-06-01
DE69008476T2 DE69008476T2 (de) 1994-09-01

Family

ID=17634937

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69008476T Expired - Fee Related DE69008476T2 (de) 1989-10-26 1990-10-26 Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose.

Country Status (6)

Country Link
US (1) US5116828A (de)
EP (1) EP0424954B1 (de)
JP (1) JP3113269B2 (de)
AT (1) ATE104854T1 (de)
DE (1) DE69008476T2 (de)
ES (1) ES2055845T3 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2119337C1 (ru) * 1992-03-21 1998-09-27 Энтек Гезельшафт фюр Эндокринологише Технологи мбХ Трансдермальный препарат продленного действия с антиостеопоротической активностью
JPH08505147A (ja) * 1992-12-29 1996-06-04 エフ． ホリック、マイケル 骨粗鬆症の治療又は予防に関するビタミンｄグリコシドの用途
IL108371A (en) * 1993-01-19 2009-09-01 Endorech Inc Use of sex steroid precursors to prepare medicaments for treatment of vaginal atrophy
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US20030170290A1 (en) * 1993-06-16 2003-09-11 Shug Austin L. Delayed release carnitine
JPH09100293A (ja) * 1995-10-03 1997-04-15 Kanebo Ltd インターロイキン８の作用増強剤
US6266622B1 (en) * 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
US6236946B1 (en) 1995-12-13 2001-05-22 Thomas S. Scanlan Nuclear receptor ligands and ligand binding domains
US6197291B1 (en) 1996-06-27 2001-03-06 Kanebo Limited Agent for potentiating the effect of interleukin-8
IT1292129B1 (it) * 1997-06-11 1999-01-25 Sunnimex Ltd Medicamento utile per ridurre la massa grassa ed aumentare la massa magra nella donna in menopausa ed in entrambi i sessi nella
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US6342611B1 (en) * 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
KR20060098400A (ko) * 1998-06-11 2006-09-18 앙도르쉐르슈 인코포레이티드 안드로스트-5-엔-3β,17β-디올을 포함하는 약학 조성물 및그 용도
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022394A1 (it) * 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
CA2546601A1 (en) * 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
DE102004025985A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estriol- und Estetrol-Prodrugs
US20050277625A1 (en) * 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
US7534780B2 (en) * 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
AU2006249348B2 (en) * 2005-05-26 2012-05-24 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
EP1898926A2 (de) 2005-05-26 2008-03-19 Metabasis Therapeutics, Inc. Thyromimetika zur behanldung von fettleber
CA2610475C (en) * 2005-07-12 2013-09-17 Warner Chilcott Company, Inc. Derivative prodrugs of ethinyl estradiol
MX2008000412A (es) * 2005-07-12 2008-03-10 Warner Chilcott Co Inc Profarmacos de 3-ester de estradiol.
TR201815853T4 (tr) 2005-10-12 2018-11-21 Besins Healthcare Sarl Hipogonadizmin tedavisinde kullanıma yönelik geliştirilmiş testosteron jeli.
US20070197488A1 (en) * 2005-11-29 2007-08-23 Olaf Peters Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
US20070123500A1 (en) * 2005-11-29 2007-05-31 Gerd Mueller Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
US20070135375A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Sulfamoyl sulfonate prodrugs
US8288366B2 (en) * 2006-06-20 2012-10-16 Chochinov Ronald H Formulation for hair growth
WO2009048072A1 (ja) * 2007-10-11 2009-04-16 Daiichi Sankyo Company, Limited 破骨細胞関連蛋白質Ｓｉｇｌｅｃ－１５を標的とした抗体
WO2010107702A1 (en) * 2009-03-16 2010-09-23 Ipintl, Llc Treating alzheimer's disease and osteoporosis and reducing aging
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6434M (de) * 1967-02-23 1968-11-04
US4041022A (en) * 1967-05-24 1977-08-09 Ciba-Geigy Corporation Process for the manufacture of thyrocalcitonin
GB2138286B (en) * 1983-04-19 1986-10-08 Dr Christopher Harry Mortimer Pharmaceutical composition for the treatment of hair loss
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
JPS6089422A (ja) * 1983-10-24 1985-05-20 Kureha Chem Ind Co Ltd 抗骨粗鬆症剤
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US5001118A (en) * 1986-12-29 1991-03-19 Kureha Kagaku Kogyo Kabushiki Kaisha Method for preventing senescence and increasing bone mass
JP2542846B2 (ja) * 1987-05-22 1996-10-09 日本臓器製薬株式会社 糖尿病治療剤
US4946679A (en) * 1988-07-25 1990-08-07 Thys Jacobs Susan Method for the treatment of premenstrual syndrome
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome

Also Published As

Publication number Publication date
JP3113269B2 (ja) 2000-11-27
ATE104854T1 (de) 1994-05-15
EP0424954B1 (de) 1994-04-27
US5116828A (en) 1992-05-26
JPH03209328A (ja) 1991-09-12
ES2055845T3 (es) 1994-09-01
DE69008476T2 (de) 1994-09-01
EP0424954A1 (de) 1991-05-02

Similar Documents

Publication Publication Date Title
DE69008476D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von Osteoporose.
CY1110287T1 (el) Χρηση της ανθρωπινης παραθυρεοειδους ορμονης
DE3752112T2 (de) Verwendung von Inositoltriphosphat zur Behandlung von Entzündungen
ATE79271T1 (de) Pharmazeutische zubereitung zur anwendung fuer die anreicherung von knochenmasse.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
GR3034162T3 (en) Liposome-encapsulated taxol, its preparation and its use
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
DK598288A (da) Vaeskeformig farmaceutisk sammensaetning til behandling af hoste og oemhed i halsen
ES8707488A1 (es) Un metodo para preparar maleato de 2-terc-butilamino-3'-cloropropiofenona
DE60028559D1 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
DK0613368T3 (da) Hudregenererende kosmetisk sammensætning
ATE94392T1 (de) In der behandlung von oestrogeninsuffizienz zu verwendende zusammensetzung.
NZ219530A (en) Composition and method for enhancing growth of mammary parenchyma
MX170055B (es) , "composicion insecticida y procedimiento para su obtencion
DE3687233T2 (de) Pharmazeutische zusammensetzungen zur behandlung von hautkrankheiten.
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE87482T1 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
EP0348664A3 (de) Monoacetoacetine enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Tumoren
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
DE3484155D1 (de) Fr-900216-verbindung, durch kultivierung von atcc 20577 gewonnen, als aktive therapeutische verbindung genutzt, und sie enthaltende antitumorale pharmazeutische zusammensetzung von fr-900216.
DE3777411D1 (de) Mittel zur verbesserung der perkutanen verabreichung von arzneimitteln.
ES8706441A1 (es) Procedimiento para preparar una composicion farmaceutica a base de sulpirida y un progestageno.
JPS52130926A (en) Medicinal composition comprising pentazocine and salicylamide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee